Increased number of shares and votes in Medivir

The number of shares and votes in Medivir has changed as a result of issuance of shares as consideration in the offer for BioPhausia and as a result of the exercise of employee stock options.

Today, the last trading day of the month, there are in total 31,174,846 shares and 37,114,846 votes in the company.

Huddinge, June 30, 2011
Medivir AB (publ)

Medivir is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08.00 am CET on June 30, 2011.

For more information about Medivir, please contact:     
Rein Piir, CFO & VP Investor Relations                                     Mobile: +46 708 537 292

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a novel protease inhibitor is in phase 3 clinical development for hepatitis C and is partnered with Tibotec Pharmaceuticals. In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir’s first product, the unique cold sore product Xerese™/Xerclear® was launched on the US market in February 2011. Xerese™/Xerclear®, which has been approved in both the US and Europe is partnered with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia and with Meda AB in North America, Canada and Mexico. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website: www.medivir.se.

Tags: